Liver transplant recipients and prioritization of anti-HCV therapy: An Italian cohort analysis

Liver International

Volumn 36, Issue 3, 2016, Pages 410-417

  Lanini, Simone ^a   Nanni Costa, Alessandro ^b   Grossi, Paolo A ^c   Procaccio, Francesco ^b   Ricci, Andrea ^b   Capobianchi, Maria R ^a   Terrault, Norah A ^d   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Donor recipient age difference; Donor recipient sex matching; Liver graft failure; MELD score; Multicentre study

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; INCIDENCE; INFORMATION SCIENCE; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT INFORMATION; RISK FACTOR; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; END STAGE LIVER DISEASE; HEALTH CARE PLANNING; HEPACIVIRUS; IMMUNOLOGY; ITALY; LIVER TRANSPLANTATION; MORTALITY; PATHOGENICITY; PATIENT SELECTION; TIME FACTOR; TREATMENT FAILURE; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; BIOMARKERS; COHORT STUDIES; END STAGE LIVER DISEASE; FEMALE; HEALTH PRIORITIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; ITALY; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; VIRUS ACTIVATION;

EID: 84958944809     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12938     Document Type: Article

References (21)

1. Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis 2014; 16: 1-16.
2. Angelico M. Epidemiology and outcome of hepatitis C relapse in transplant recipients. Transplant Proc 2011; 43: 2457-8.
3. European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. 2014. Available at http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-ofhepatitis-c-2014. Accessed 18 June 2014.
4. American Association for the Study of the Liver Diseases Recommendations for Testing, Managing, and Treating Hepatitis C. Available at http://www.hcvguidelines.org/. Accessed 18 June 2014.
5. Gurusamy KS, Tsochatzis E, Toon CD, et al. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst Rev 2013; 12: CD006803.
6. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007; 26: 5512-28.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. Hepatology 2001; 33: 464-70. Review.
8. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med 2004; 23: 369-88.
9. Gelman A. P values and statistical practice. Epidemiology 2013; 24: 69-72.
10. Ippolito G, Antonelli G, Capobianchi MR, Lanini S. HCV treatment revolution: needs for close monitoring. Clin Microbiol Infect 2014; 20: 790-1.
11. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1003-19.
12. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
13. Briceño J, Ciria R. Early graft dysfunction after liver transplantation. Transplant Proc 2010; 42: 631-3. doi:10.1016/j.transproceed.2010.02.004. Review.
14. Rana A, Kaplan B, Jie T, et al. A critical analysis of early death after adult liver transplants. Clin Transplant 2013; 27: E448-53.
15. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-14.
16. Kemmer N, Neff G. Recipient-based approach to tailoring immunosuppression in liver transplantation. Transplant Proc 2010; 42: 1731-7.
17. Chedid MF, Rosen CB, Nyberg SL, Heimbach JK. Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors. HPB (Oxford) 2014; 16: 852-8.
18. Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331-9.
19. Meije Y, Fortún J, Len O, et al. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 2014; 16: 387-96.
20. Danziger-Isakov L, Bucavalas J. Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers. Am J Transplant 2014; 14: 1908-11.
21. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012; 56: 973-83.